骨髓瘤——1986 - 1990年治疗结果
Myeloma--results of treatment 1986-1990.
作者信息
Kettle P, Ranaghan L, Markey G M, Robertson J H, Desai Z R, Bharucha C, Morris T C
机构信息
Haematology Department, Belfast City Hospital.
出版信息
Ulster Med J. 1993 Apr;62(1):11-20.
Sixty-nine patients with multiple myeloma diagnosed during a five year period at the Belfast City Hospital were followed until death or for a minimum of one year in a retrospective study of survival. Although the patients were unselected, survival data was found to be similar to results from trials in which patient selection had occurred. Overall median survival was thirty-two months. Median survival fell with advancing disease and was 47, 27 and 18 months for Durie-Salmon stages I, II and III respectively. Those patients presenting with a platelet count of < 100 x 10(9)/1 had a median survival of eight months in contrast to those with a platelet count > 100 x 10(9)/1 whose median survival was 36 months. Patients presenting in renal failure had a shorter median survival of 28 months compared to 46 months for those with normal renal function.
在一项关于生存情况的回顾性研究中，对贝尔法斯特城市医院在五年期间诊断出的69例多发性骨髓瘤患者进行了随访，直至死亡或至少随访一年。尽管这些患者未经过挑选，但发现生存数据与经过患者挑选的试验结果相似。总体中位生存期为32个月。中位生存期随疾病进展而下降，Durie-Salmon分期I、II和III期的中位生存期分别为47个月、27个月和18个月。血小板计数<100×10⁹/L的患者中位生存期为8个月，而血小板计数>100×10⁹/L的患者中位生存期为36个月。出现肾衰竭的患者中位生存期较短，为28个月，而肾功能正常的患者中位生存期为46个月。
Zotero 插件